[Seroprevalence study of hepatitis B among orienteers]

Med Clin (Barc). 2009 May 9;132(17):649-53. doi: 10.1016/j.medcli.2008.09.041. Epub 2009 Apr 22.
[Article in Spanish]

Abstract

Background and objective: Our objectives were to detect asymptomatic cases involved in an outbreak of hepatitis B, to assess the seroprevalence of hepatitis B (HB) in orienteers and to establish recommendations.

Patients and method: One hundred sixteen orienteers who had competed in the categories involved in the previous outbreak as well as a stratified random sample of 166 of the remaining orienteers in other competition categories were included in a cross-sectional serological prevalence study. HB surface antigen (anti-HBs); total antibody to HB core antigen (total anti-HBc); HB surface antigen (Ag HBs); and antibody IgM to HB core antigen (anti-HBcIgM) along with the history of vaccination for hepatitis B were analyzed. The results were weighted.

Results: The seroprevalence of HB (total anti-HBc positive) was 6.7% (n=12, 95% CI 0.6-12.9). No case of acute HB or chronic infection was observed. All the serological markers were negative for 61.1% (n=64, 95% CI 46.3-75.6), and 31.5% (n=29, 95% CI 18.2-46.4) had markers of immunity due to vaccination. Among individuals under 25 years of age, 28.4% were unvaccinated, although they were covered by vaccination programs.

Conclusion: Our results suggest that the seroprevalence of HB among orienteers is not different from the general population in Spain. However, it is necessary to reinforce the vaccination among adolescents and young adults. General recommendations for the prevention of HB were made to orienteering federations.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Disease Outbreaks*
  • Female
  • Hepatitis B / blood*
  • Hepatitis B / epidemiology*
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Core Antigens / immunology
  • Humans
  • Male
  • Seroepidemiologic Studies
  • Spain / epidemiology
  • Sports*
  • Young Adult

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens